Citation: | HUANGQian, LIUYong-gang, LIJing-tao, WEIHai-liang, YANShu-guang, ZHANGHai-bo, CHANGZhan-jie. Effects of Xiaomudan Granules on the Expressions of FXR and ApoM in Rats with Non-Alcoholic Fatty Liver Disease[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(4): 478-484. |
[1] |
TRAUSSNIGG S,KIENBACHER C,HALILBASIC E,et al.Challenges and management of liver cirrhosis:Practical issues in the therapy of patients with cirrhosis due to NAFLD and NASH[J].Dig Dis,2015,33(4):598-607.
|
[2] |
KWOK R,TSE YK,WONG GL,et al.Systematic review with meta-analysis:Non-invasive assessment of non-alcoholic fatty liver disease:the role of transient elastography and plasma cytokeratin-18 fragments[J].Aliment Pharmacol Ther,2014,39(3):254-269.
|
[3] |
WONG RJ, CHEUNG R, AHMED A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S[J]. Hepatology, 2014,59(6):2188-2195.
|
[4] |
LINDOR KD.Farnesoid X receptor agonists for primary biliary cirrhosis[J].Curr Opin Gastroenterol,2011,27(3):285-288.
|
[5] |
黄倩,李京涛,魏海梁,等. 法尼醇受体对非酒精性脂肪性肝病作用研究进展[J]. 中国肝脏病杂志(电子版),2019,11(3):21-25.
|
[6] |
任坤,唐振丽,易光辉.载脂蛋白M[J].中国生物化学与分子生物学报,2015,31(6):557-565.
|
[7] |
张艳,刘红,彭家和,等.激活类法尼醇X核内受体(FXR)可下调载脂蛋白M在HepG2细胞中的表达[J].中国生物化学与分子生物学报,2009,25(11):1030-1034.
|
[8] |
ZHU C, DI D, ZHANG X, et al. TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells[J]. Lipids Health Dis,2011,10: 199.
|
[9] |
刘亚珠,李京涛,席奇.消木丹颗粒治疗非酒精性脂肪性肝病气郁痰阻证临床观察[J].北京中医药,2016,35(3):214-217.
|
[10] |
刘宝咸,席奇,南然,等.综合护理干预联合消木丹颗粒治疗30例单纯性脂肪肝疗效观察[J].现代中医药,2016,36(5):22-24.
|
[11] |
焦俊喆,关茜,王轲,等.消木丹颗粒联合恩替卡韦治疗慢性乙型病毒性肝炎合并非酒精性脂肪肝临床研究[J].四川中医,2018,36(9):80-83.
|
[12] |
吕宝伟,冯春青,孙建光.补肾降浊饮对非酒精性脂肪肝大鼠胰岛素抵抗的影响[J].中国实验方剂学杂志,2018,24(12):107-113.
|
[13] |
陈奇.中药药理研究方法学[M].2版.北京:人民卫生出版社,2006:28.
|
[14] |
XU JS,LI YY,CHEN WD,et al.Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis[J].Hepatology,2014,59(5):1761-1771.
|
[15] |
REN K,TANG ZL,JIANG Y,et al.Apolipoprotein M[J].Clin Chim Acta,2015,446:21-29.
|
[16] |
左小炫. ApoM基因在非酒精性脂肪性肝病形成中的作用[D].芜湖:皖南医学院,2018.
|
[17] |
丁静,张斌,王培劼,等.基于数据挖掘和生物信息分析探讨非酒精性脂肪肝用药规律及作用机制[J].中国中药杂志,2019,44(8):1689-1695.
|
[18] |
宋保兰.陈皮药理作用[J].实用中医内科杂志,2014,28(8):132-133,160.
|
[19] |
邢增智,陈旺,曾宇.泽泻的化学成分与药理作用研究进展[J].中医药导报,2017,23(15):75-78.
|
[20] |
董晓强,尹占芳.决明子的化学成分及药理作用研究[J].中国当代医药,2013,20(7):18-19,23.
|
[21] |
吴鹏波,宋琪,俞媛洁,等. 姜黄素对非酒精性脂肪肝细胞模型保护作用以及机制研究[J]. 实用肝脏病杂志,2020,23(3):324-327.
|
[22] |
梁学清,李丹丹,黄忠威.茯苓药理作用研究进展[J].河南科技大学学报(医学版),2012,30(2):154-156.
|
[23] |
ZHU CH,DI DM,ZHANG XY,et al.TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells[J].Lipids Health Dis,2011,10:199.
|